Meet Our Attorneys
CTTG’s attorneys have extensive experience in technology transfer. As technology transfer professionals at the National Institutes of Health, they assisted government scientists and researchers to establish partnerships with industry for the development of a wide range of technology. In private practice they have represented pharmaceutical companies, medical device and dietary supplement manufacturers, law firms, and academic medical centers on technology transfer matters and regulatory issues concerning the clinical research and development of drugs, medical devices, natural products, and dietary supplements.
Kate Duffy Mazan is an attorney in private practice in McLean, VA. She is the founding member of The Clinical Technology Transfer Group (CTTG). CTTG is a law firm concentrating in technology transfer and regulatory compliance in the clinical setting.
For the past 15 years Kate has practiced exclusively in the area of food and drug law with an emphasis on the regulation of clinical research. In private practice she has assisted a variety of companies and institutions in complying with federal and state laws and regulations governing the conduct of clinical trials. Kate has extensive experience in the negotiation of clinical trial agreements and the regulatory review of clinical research practices. Prior to entering private practice, Kate worked for nine years at the National Cancer Institute (NCI) within the National Institutes of Health. As a technology transfer professional at NIH she managed the intellectual property portfolio of NCI’s Natural Products Branch, negotiating CRADAs and international agreements with countries in Africa, Central and South America, and the Pacific rim. Kate also worked with scientists from several other institutes within NIH to develop a wide range of technology. She began her career at NIH as Chief of NCI’s Cancer Information Service (CIS), a nationwide network of cancer information and education programs located at major cancer centers across the country. In that capacity she was responsible for developing a training program on the conduct of clinical trials to assist information specialists explain clinical research to patients and the public.
Kate holds a law degree from the Columbus School of Law at the Catholic University of America, Washington, D.C., a Master of Science in Public Health Administration from the University of Massachusetts Amherst, and an A.B. from Stonehill College, North Easton, Massachusetts. Kate is admitted to practice law in Virginia, Maryland, and the District of Columbia.
Jeremy Cubert joined CTTG in 2012 with a focus on intellectual property law in the life sciences. He has over 17 years of experience in patent law and assists companies in all aspects of obtaining and managing their intellectual property portfolios. Jeremy has extensive experience in due diligence and analysis of intellectual property portfolios and counsels clients regarding the acquisition and licensing of intellectual property assets. He also drafts and prosecutes patents in the biotechnology, pharmaceutical, and mechanical arts. Jeremy was a member of patent litigation team that secured over $1 billion dollars in judgments for a medical device client. He has extensive experience working directly with scientists and professionals at academic institutions, biotechnology companies, and Fortune 500 companies to develop intellectual property development and management plans.
Prior to entering private practice, Jeremy was a staff attorney at the Federal Trade Commission and Technology Transfer Specialist at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) where he managed the intellectual property portfolio for nine institutes at the NIH.
Jeremy is currently an Adjunct Professor at the American University Washington College of Law where he teaches a course entitled “Intellectual Property Law and Healthcare” and has authored many articles in the area of intellectual property law. He holds a law degree from the George Mason University School of Law, a Master’s Degree in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of New Jersey, and a BA in Biology from Rutgers University.
Kathleen Sybert has over twenty years of experience in the life sciences, including as a researcher and inventor in the biotechnology industry, and as a technology transfer professional at the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
At NCI, Kathleen served as Chief of the Technology Transfer Branch, supervising a staff of professionals with backgrounds in law, science, medicine and business management, who served the technology transfer needs of M.D. and Ph.D. scientists at twelve of NIH’s Institutes and Centers. Kathleen advised pharmaceutical and other commercial organizations as well as universities and other non-profit institutions about the compatibility of their proposed projects with the research and development goals of NCI, especially those of the Developmental Therapeutics and Cancer Therapy Evaluation Programs of the Division of Cancer Treatment and Diagnosis. Kathleen also advised commercial and non-profit recipients of federal funding about the government’s rights and interests in inventions made under grants and contracts, including Small Business Innovation Research awards (SBIRs), and cooperative agreements. She worked closely with industrial, academic and federal scientists, attorneys and business managers in drafting and negotiating Cooperative Research and Development Agreements (CRADAs), clinical trial agreements, material transfer agreements and confidential disclosure agreements. Kathleen also participated in revising model agreements for NCI and NIH, including license agreements. While at NCI, Kathleen team taught the technology transfer course at the Foundation for Advanced Education in the Sciences graduate school at NIH, and served a term as Chair of the NIH Technology Development Coordinators, which included sitting with the Public Health Service Technology Transfer Policy Board.
Before joining NCI, Kathleen was a research scientist at three Maryland biotechnology corporations, including the Viral Science Laboratory of Electronucleonics Laboratories, where she helped established their first Institutional Biosafety Committee; Igene Biotechnology, where she participated in the company’s start-up phase; and Advanced technologies, where she worked in a Biosafety–Level 3 laboratory environment.
Kathleen is co-author of an Association of University Technology Managers (AUTM) Technology Transfer Practice Manual chapter on CRADAs, and a Practicing Law Institute Biotechnology Patents and Business Strategies program paper entitled Government Funding and Research and Development Collaborations with Biotechnology Companies.
Kathleen holds a law degree from the Washington College of Law at American University, Washington, D.C., and a Ph.D. in Biology from the University of Maryland. She is admitted to practice law in Maryland, Pennsylvania, and before the United States Patent and Trademark Office.
Nancy brings a uniquely diverse background in regulatory practice in regulated industry. For over ten years Nancy was a legislative and regulatory counsel for the American Insurance Association. She had responsibility for a diverse portfolio of regulatory practice areas, including rate making, regulatory compliance, automobile insurance, anti-trust, surplus lines and surety. Nancy regularly advised representatives of large nationwide property/casualty insurance companies, lobbyists, and regulators on a full array of regulatory issues in these areas. She had responsibility for testifying before state legislatures and regulatory agencies on legislative and regulatory initiatives affecting member companies, and developed and communicated policy positions to industry lobbyists and regulators. She coordinated policy with industry organizations, specialty boards, trade associations, and major insurance companies. Nancy also published a comprehensive 50-state survey and analysis of property/casualty insurance rate laws as well as a similar guide for workplace drug testing laws.